Table 1.
Baseline characteristics of patients with inoperable CTEPH
| Variables | Values |
|---|---|
| Patients, n | 25 |
| Male/Female, n | 13/12 |
| Age, years | 58.2 ± 9.8 |
| BMI, kg/m2 | 23.6 ± 3.4 |
| WHO-FC I/II/III/IVa, n | 1/11/13/0 |
| DVT, n (%) | 8 (32%) |
| Duration from onset to admissiona, years | 3.0 (1.1–5.5) |
| SaO2a, % | 91.3 ± 2.3 |
| SvO2a, % | 68.9 ± 5.3 |
| mRAPa, mmHg | 7.4 ± 3.3 |
| mPAPa, mmHg | 49.4 ± 13.4 |
| PVRa, dyne·s·cm−5 | 952.01 ± 375.38 |
| CIa, l/min/m2 | 3.18 ± 0.74 |
| PAWPa, mmHg | 10.2 ± 3.0 |
| PH targeted medicationa, n (%) | 19 (76%) |
| Monotherapy, n (%) | 14 (56%) |
| ERAs | 2 (8%) |
| PDE-5is | 8 (32%) |
| sGCs | 4 (16%) |
| Combined therapy, n (%) | 5 (20%) |
| ERAs+PDE-5is, n (%) | 5 (20%) |
| 6MWDa, m | 331.8 ± 111.3 |
| Number of BPA sessions, n | 40 |
| Number of treated segments per session, n | 3.4 ± 1.6 |
| Number of treated vessels per session, n | 4.6 ± 1.9 |
| Number of balloons per session, n | 1.4 ± 0.5 |
BMI body mass index, WHO-FC WHO functional class, DVT deep vein thrombosis, SaO2 arterial oxygen saturation, SvO2 mixed venous oxygen saturation, mRAP mean right atrial pressure, mPAP mean pulmonary artery pressure, PVR pulmonary vascular resistance, CI cardiac index, PAWP pulmonary arterial wedge pressure, PH pulmonary hypertension, ERAs endothelin receptor antagonists, PDE-5is phosphodiesterase-5 inhibitors, sGCs soluble guanylate cyclase stimulators, 6MWD 6-min walk distance, BPA balloon pulmonary angioplasty
aData at the first admission